Pharvaris N.V. (FRA:9EN)
Germany · Delayed Price · Currency is EUR | Market Cap | 2.24B +57.1% |
| Revenue (ttm) | n/a |
| Net Income | -170.92M |
| EPS | -2.62 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 31.35 |
| Previous Close | 31.80 |
| Day's Range | 31.35 - 31.95 |
| 52-Week Range | 17.80 - 32.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 27, 2026 |
About Pharvaris
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE a... [Read more]
Financial Performance
Financial StatementsNews
Pharvaris reports Q2 EPS (EUR 0.70) vs. (EUR 0.83) last year
Cash and cash equivalents were EUR 318M as of June 30, 2026, compared to EUR 292M for December 31, 2025. “Pharvaris (PHVS) continues to make strong progress advancing deucrictibant IR…
Pharvaris price target raised to $75 from $74 at Citizens
Citizens raised the firm’s price target on Pharvaris (PHVS) to $75 from $74 and keeps an Outperform rating on the shares. Positive Phase 3 CHAPTER-3 data could drive shares materially…
Pharvaris price target raised to $38 from $35 at BofA
BofA raised the firm’s price target on Pharvaris (PHVS) to $38 from $35 and keeps a Neutral rating on the shares. The firm updated estimates for Q2 results, cash and…
Pharvaris price target raised to $40 from $39 at Guggenheim
Guggenheim raised the firm’s price target on Pharvaris (PHVS) to $40 from $39 and keeps a Buy rating on the shares while awaiting the outcome of the CHAPTER-3 Phase 3…
Pharvaris Earnings release: Q2 2026
Pharvaris released its Q2 2026 earnings on August 12, 2026, summarizing the period's financial results.
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update
ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology
ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Pharvaris price target raised to $35 from $33 at BofA
BofA raised the firm’s price target on Pharvaris (PHVS) to $35 from $33 and keeps a Neutral rating on the shares ahead of the company’s expected topline phase 3 CHAPTER-3…
Pharvaris announces publication of review article on bradykinin
Pharvaris (PHVS) announced the publication of a comprehensive review article in Clinical Reviews in Allergy & Immunology providing a state-of-the-art overview of the biology of bradykinin and the brad...
Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema
ZUG, Switzerland, July 22, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Pharvaris initiated with an Overweight at Wells Fargo
Wells Fargo analyst Yanan Zhu initiated coverage of Pharvaris (PHVS) with an Overweight rating and $55 price target The firm views the company’s deucrictibant as one of the best positioned…
Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks
ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Pharvaris price target raised to $46 from $41 at Morgan Stanley
Morgan Stanley analyst Maxwell Skor raised the firm’s price target on Pharvaris (PHVS) to $46 from $41 and keeps an Overweight rating on the shares. Noting that topline data is…
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of t...
Pharvaris Announces Annual General Meeting of Shareholders
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet nee...
Pharvaris management to meet with Oppenheimer
Meeting to be held on June 8 hosted by Oppenheimer.
Pharvaris management to meet with Oppenheimer
Meeting to be held on June 5 hosted by Oppenheimer.
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
ZUG, Switzerland, May 29, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet need...
Pharvaris Transcript: RBC Capital Markets Global Healthcare Conference 2026
Deucrictibant IR demonstrated rapid and durable efficacy in acute HAE attacks, outperforming current standards in key endpoints. The oral formulation is expected to expand treatment rates and reduce burden, with NDA filing on track and commercial infrastructure in place. The XR formulation targets once-daily prophylaxis, and the portfolio aims to address both on-demand and preventive needs.
Pharvaris price target raised to $33 from $31 at BofA
BofA raised the firm’s price target on Pharvaris (PHVS) to $33 from $31 and keeps a Neutral rating on the shares after having hosted CFO David Nassif for a fireside…
Pharvaris Transcript: Bank of America Global Healthcare Conference 2026
Raised €132M to fund launches through 2028, with ODT NDA filing and Prophy data readout expected in 2026. RAPIDe-3 met all endpoints, showing rapid, durable efficacy. Commercial buildout targets 90 staff by 2027, aiming for leadership in both on-demand and prophylactic HAE markets.
Pharvaris price target lowered to $74 from $75 at Citizens
Citizens lowered the firm’s price target on Pharvaris (PHVS) to $74 from $75 and keeps an Outperform rating on the shares. The Phase 3 CHAPTER-3 readout in Q3 is the…
Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year
Cash and cash equivalents were EUR 247 million as of March 31, 2026, compared to EUR 292 million for December 31, 2025. “In 2026, Pharvaris (PHVS) remains focused on execution…
Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update
Topline data from CHAPTER-3, a pivotal Phase 3 study of deucrictibant XR for the prophylaxis of HAE attacks, expected in 3Q2026 Timeline for submission of NDA of deucrictibant IR for the on-demand tre...
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
ZUG, Switzerland, May 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris N.V. (“Pharvaris,” Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help ...